MaxCyte signs multi-platform technology license deal with Genentech to support cell therapy development

MaxCyte, Inc.

MaxCyte, Inc.

MXCT

0.00
  • MaxCyte entered a technology license partnership with Genentech to support development of multiple cell therapy programs.
  • License gives Genentech access to MaxCyte’s ExPERT GTx platform across select research, clinical development, manufacturing workflows.
  • Deal targets ex vivo cell-engineering applications, aiming to streamline progress from early discovery through cGMP manufacturing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MaxCyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607210805PRIMZONEFULLFEED9764808) on July 21, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.